Who makes Elranatamab + Nirogacestat?

Elranatamab + Nirogacestat is developed by Pfizer Inc..

What development phase is Elranatamab + Nirogacestat in?

Elranatamab + Nirogacestat is in Phase 2.

What is the generic name of Elranatamab + Nirogacestat?

elranatamab-nirogacestat is the generic (nonproprietary) name of Elranatamab + Nirogacestat.

Last reviewed 2026-04-20 · How we verify

Elranatamab + Nirogacestat (elranatamab-nirogacestat)

Pfizer Inc. · Phase 2 active Bispecific antibody Quality 0/100

At a glance

Generic name	elranatamab-nirogacestat
Sponsor	Pfizer Inc.
Modality	Bispecific antibody
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Elranatamab + Nirogacestat CI brief — competitive landscape report
Elranatamab + Nirogacestat updates RSS · CI watch RSS
Pfizer Inc. portfolio CI